New asthma drug IBI3002 enters first human tests
NCT ID NCT07015749
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug, IBI3002, in adults with asthma that is not fully controlled by their current inhalers. About 12 to 27 participants will receive either the drug or a placebo by injection to see if it is safe and how the body processes it. The study is small and focused on safety, not yet on whether the drug improves asthma symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3002
- What this could lead to
- If it works, this could point toward a new treatment option for people with asthma that is not well controlled by current inhalers.
- What could go wrong
- This is a very early Phase 1 trial with only 12–27 participants, so it is primarily checking safety and dosing. It is too small and early to know if the drug actually helps asthma symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?